The Bio Report spoke to Anat Cohen-Dayag, CEO of Compugen, about the company’s discovery platform, its efforts to develop new treatments that address patients who don’t respond to current checkpoint inhibitors, and its clinical pipeline in development.

The Bio Report sat down with Adam Feuerstein, senior writer for Stat and the publication’s national biotech columnist, to discuss the year that was in biotech, the trends that drove the numbers, and what’s ahead in 2021.